phosphoinositide 3-kinase delta inhibitor

Phosphoinositide 3-kinase delta (PI3Kδ) inhibitors are a class of targeted therapies, typically small molecules, designed to inhibit the delta isoform of the p110 catalytic subunit of PI3K. Unlike other PI3K isoforms (alpha and beta) which are ubiquitously expressed, PI3Kδ is primarily restricted to hematopoietic cells, particularly leukocytes. This selective expression makes it a key regulator of immune cell signaling, including B-cell receptor signaling and T-cell activation and differentiation. Clinically, PI3Kδ inhibitors are approved for the treatment of certain B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. Emerging research, as highlighted in recent studies, also investigates their role in modulating regulatory T-cell (Treg) biology and their potential impact on inflammatory conditions like atherosclerosis, where PI3Kδ signaling appears to play a protective role by maintaining Treg stability and immunosuppressive function.

Other names

PI3K delta inhibitorPI-3K delta inhibitorPI 3K delta inhibitorPI3Kδ inhibitorPI3Kd inhibitorPI-3Kd inhibitorPI 3Kd inhibitorPhosphatidylinositol 3-kinase delta inhibitorPhosphatidylinositol3-kinase delta inhibitorPhosphatidylinositol-3-kinase delta inhibitor